DPP4 and Hypoglycemia: The new generation of glucose-lowering medications, such as glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT-2) inhibitors may pose a lower risk for hypoglycaemia [30].